enGene Therapeutics Inc ENGN

1.96 0.04 2.08% as of 25 Sep
Market cap
$128.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Older periods Oct '25 Jan '26 Apr '26 Jul '26
Current Ratio

+8 more quarters

6.30 11.75 12.57 10.21
Net Debt/EBITDA
4.49 7.96 7.24 7.07
Debt/Assets
6.92% 7.34% 8.10% 8.72%
Debt/Equity
0.09 0.09 0.10 0.11
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.66 0.97 1.01 0.58
Capex/Depreciation
1.74 0.38 0.31 0.00
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.50) (0.43) (0.44) (0.27)
Cash per Share
3.79 4.10 3.71 3.82
Shareholders Equity per Share
3.28 4.19 3.66 3.30
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
3.28 4.19 3.66 3.30
Free Cash Flow
(25.40) (29.06) (30.60) (18.95)
Working Capital
169.41 264.61 248.52 250.69
Capital Expenditures
(0.44) (0.15) (0.10) 0.00
Net Current Asset Value
147.63 233.65 217.64 219.87
Other line items
Quick Ratio
6.09 11.26 12.07 9.83
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.49) (0.43) (0.44) (0.27)
Capex per Share
(0.01) 0.00 0.00 0.00
Average Receivables
0.63 0.81 0.68 0.84
Average Payables
4.05 2.52 1.68 2.46
Average Assets
266.32 311.52 287.09 266.94
Average Common Equity
220.16 265.75 241.23 215.48
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates